IMMX
Immix Biopharma, Inc. (NASDAQ)
Healthcare — Biotechnology
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Strong Buy
1.3 / 5
7 analysts
$9.83
$-0.48 (-4.66%)
Target:
$19.75
(101.0%)
Sign in to add IMMX to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $699.80M |
| P/E Ratio (TTM) | - |
| Forward P/E | -13.25 |
| EPS (TTM) | $-0.92 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -74.46% |
| Debt/Equity | 1.23 |
| Recommendation | Strong Buy 1.3 |
| Analyst Target | $19.75 |
| Analysts | 7 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 68.0 |
| Beta | 0.11 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $11.61 |
| 52-Week Low | $1.94 |
| 50-Day Avg | $9.24 |
| 200-Day Avg | $6.61 |
| Avg Volume | $1.38M |
| Volume | $1.82M |
Performance Analysis
BULLISHIMMX shows predominantly bullish signals based on its fundamentals and technicals.
+
Showing strength at 82% of its 52-week range.
+
RSI at 68.0 shows positive momentum.
+
Price is above both the 50-day and 200-day moving averages — strong uptrend.
+
Wall Street consensus is "Strong Buy" from 7 analysts.
+
Average analyst target of $19.75 implies 101.0% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:15 UTC
Back to Screener Export Report